SG10201605435TA - Agr2 blocking antibody and use thereof - Google Patents

Agr2 blocking antibody and use thereof

Info

Publication number
SG10201605435TA
SG10201605435TA SG10201605435TA SG10201605435TA SG10201605435TA SG 10201605435T A SG10201605435T A SG 10201605435TA SG 10201605435T A SG10201605435T A SG 10201605435TA SG 10201605435T A SG10201605435T A SG 10201605435TA SG 10201605435T A SG10201605435T A SG 10201605435TA
Authority
SG
Singapore
Prior art keywords
blocking antibody
agr2
agr2 blocking
antibody
blocking
Prior art date
Application number
SG10201605435TA
Other languages
English (en)
Inventor
Dawei Li
Zhenghua Wu
Hao Guo
Qi Zhu
Dhahiri S Mashausi
Original Assignee
Sanofi China Invest Co Ltd Shanghai Branch
Univ Shanghai Jiaotong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi China Invest Co Ltd Shanghai Branch, Univ Shanghai Jiaotong filed Critical Sanofi China Invest Co Ltd Shanghai Branch
Publication of SG10201605435TA publication Critical patent/SG10201605435TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG10201605435TA 2011-07-05 2012-07-05 Agr2 blocking antibody and use thereof SG10201605435TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2011101864695A CN102268089A (zh) 2011-07-05 2011-07-05 Agr2阻断抗体及其用途

Publications (1)

Publication Number Publication Date
SG10201605435TA true SG10201605435TA (en) 2016-08-30

Family

ID=45050566

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201605435TA SG10201605435TA (en) 2011-07-05 2012-07-05 Agr2 blocking antibody and use thereof

Country Status (13)

Country Link
US (2) US9574012B2 (fr)
EP (1) EP2749573B1 (fr)
JP (1) JP6127043B2 (fr)
KR (1) KR20140093922A (fr)
CN (2) CN102268089A (fr)
AU (1) AU2012278751B2 (fr)
BR (1) BR112014000181A2 (fr)
CA (1) CA2841372A1 (fr)
MX (1) MX347320B (fr)
RU (1) RU2610665C2 (fr)
SG (1) SG10201605435TA (fr)
TW (1) TWI588154B (fr)
WO (1) WO2013004076A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102268089A (zh) * 2011-07-05 2011-12-07 上海交通大学 Agr2阻断抗体及其用途
KR101588285B1 (ko) * 2013-06-04 2016-01-25 한국생명공학연구원 소포체 스트레스로 인한 세포사멸을 약화시키는 agr2 호모-다이머
US8999007B2 (en) * 2013-07-12 2015-04-07 Ostara Nutrient Recovery Technologies Inc. Method for fines control
SG11201600565VA (en) 2013-08-02 2016-02-26 Agency Science Tech & Res Mutated internal ribosomal entry site (ires) for controlled gene expression
JP2017534251A (ja) * 2014-09-09 2017-11-24 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ａｇｒ２およびその受容体ｃ４．４ａに対する遮断モノクローナル抗体
CN104593333B (zh) * 2014-12-12 2017-07-21 上海交通大学 稳定表达抗agr2人源化单克隆抗体的cho细胞株及其应用
KR101634612B1 (ko) * 2015-12-29 2016-06-29 한국생명공학연구원 소포체 스트레스로 인한 세포사멸을 약화시키는 agr2 호모-다이머
WO2017156280A1 (fr) * 2016-03-09 2017-09-14 Viba Therapeutics, Inc. Méthodes de traitement du cancer à l'aide d'anticorps monoclonaux dirigés contre agr2 et c4.4a
CN106632680A (zh) * 2016-12-27 2017-05-10 上海交通大学 植物体系表达人源化抗agr2单克隆抗体18a4的质粒构建
AU2019330487A1 (en) * 2018-08-30 2021-02-04 Université de Montréal Proteogenomic-based method for identifying tumor-specific antigens
US20210340278A1 (en) * 2018-10-04 2021-11-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of mucosal inflammatory diseases
CN109576229A (zh) * 2018-12-13 2019-04-05 华中科技大学同济医学院附属协和医院 一种分泌抗agr2的单克隆抗体杂交瘤细胞株及其应用
CN113336853B (zh) * 2020-11-04 2022-06-14 华中科技大学同济医学院附属协和医院 针对agr3蛋白的单克隆抗体、制备方法及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
WO2002036142A2 (fr) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Methodes et compositions destinees a inhiber grb7
GB0222787D0 (en) * 2002-10-02 2002-11-06 Univ Liverpool Metastasis inducing compounds
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
CN101370525B (zh) 2005-08-19 2013-09-18 Abbvie公司 双重可变结构域免疫球蛋白及其用途
GB0611116D0 (en) * 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
GB0616929D0 (en) * 2006-08-26 2006-10-04 Univ Liverpool Antibodies, assays and hybridomas
MX2011000655A (es) * 2008-07-18 2011-03-21 Oragenics Inc Composiciones para la deteccion y tratamiento de cancer colorrectal.
KR100983386B1 (ko) 2008-09-12 2010-09-20 성균관대학교산학협력단 난소암 진단을 위한 ａｇｒ-2의 신규한 용도
CN101519649B (zh) * 2009-01-22 2010-11-03 上海交通大学 杂交瘤细胞株及其制备方法
WO2012100339A1 (fr) * 2011-01-27 2012-08-02 University Health Network Procédés et compositions pour la détection du cancer du pancréas
US9415088B2 (en) * 2011-02-25 2016-08-16 The Board Of Trustees Of The Leland Stanford Junior University Use of AGR3 for treating cancer
CN102268089A (zh) 2011-07-05 2011-12-07 上海交通大学 Agr2阻断抗体及其用途
WO2013059885A2 (fr) 2011-10-28 2013-05-02 Cephalon Australia Pty Ltd Produits de recombinaison de polypeptide et utilisations de ceux-ci

Also Published As

Publication number Publication date
RU2610665C2 (ru) 2017-02-14
CN103987731A (zh) 2014-08-13
AU2012278751A1 (en) 2014-02-27
CN103987731B (zh) 2018-04-13
JP2014520511A (ja) 2014-08-25
US20170240651A1 (en) 2017-08-24
RU2014103784A (ru) 2015-08-10
CA2841372A1 (fr) 2013-01-10
WO2013004076A8 (fr) 2014-02-06
AU2012278751A8 (en) 2014-03-27
KR20140093922A (ko) 2014-07-29
TW201319085A (zh) 2013-05-16
US9574012B2 (en) 2017-02-21
TWI588154B (zh) 2017-06-21
MX347320B (es) 2017-04-21
AU2012278751B2 (en) 2017-07-20
BR112014000181A2 (pt) 2017-02-07
EP2749573B1 (fr) 2017-09-13
EP2749573A1 (fr) 2014-07-02
MX2014000260A (es) 2014-09-01
WO2013004076A1 (fr) 2013-01-10
EP2749573A4 (fr) 2015-03-04
US20140328829A1 (en) 2014-11-06
CN102268089A (zh) 2011-12-07
JP6127043B2 (ja) 2017-05-10

Similar Documents

Publication Publication Date Title
HUS2100034I1 (hu) ANGPTL3-ellenes antitestek és alkalmazásaik
IL288203A (en) Meditops and Meditop binding antibodies and their use
IL281250A (en) Anti-PHF-tau antibodies and uses thereof
HUS2000056I1 (hu) ANTI-PD-L1 ellenanyagok és alkalmazásaik
DK2729170T3 (en) Antibody variants and uses thereof
IL232399A0 (en) Anti-2fgfr antibodies and their use
EP2756094A4 (fr) Anticorps anti-b7-h4 et leurs utilisations
SG10201605435TA (en) Agr2 blocking antibody and use thereof
HK1199842A1 (en) Anti-siglec-15 antibodies and uses thereof -15
EP2785738A4 (fr) Anticorps anti-npy et anti-pyy et leurs utilisations